[1] 中华医学会感染病学分会. 终末期肝病合并感染诊治专家共识. 中华肝脏病杂志, 2018,26:568-578.
[2] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019,13:353-390.
[3] Itoh T. Stem/progenitor cells in liver regeneration. Hepatology, 2016,64:663-668.
[4] Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms, and management. Nat Rev Gastroenterol Hepatol, 2016,13:131-149.
[5] Ko S, Russell JO, Molina LM, et al. Liver Progenitors and Adult Cell Plasticity in Hepatic Injury and Repair: Knowns and Unknowns. Annu Rev Pathol, 2020,15:23-50.
[6] Wan Z, You S, Rong Y, et al. CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure. Dig Dis Sci, 2013,58:448-457.
[7] Casulleras M, Zhang IW, López-Vicario C, et al. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells, 2020,9:2632.
[8] Wu W, Sun S, Wang Y, et al. Circulating Neutrophil Dysfunction in HBV-Related Acute-on-Chronic Liver Failure. Front Immunol, 2021,12:620365.
[9] Di Campli C, Zocco MA, Saulnier N, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis, 2007,39:1071-1076.
[10] Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology, 2012,142:505-512.e1.
[11] Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2013,19:1104-1110.
[12] 许祥, 刘晓燕, 陈婧, 等. 粒细胞集落刺激因子治疗乙型肝炎相关慢加急性肝衰竭随机对照临床研究. 传染病信息, 2016,29:279-283.
[13] Spahr L, Lambert JF, Rubbia-Brandt L, et al. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology, 2008,48:221-229.
[14] Prajapati R, Arora A, Sharma P, et al. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial. Eur J Gastroenterol Hepatol, 2017,29:448-455.
[15] Singh V, Keisham A, Bhalla A, et al. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. Clin Gastroenterol Hepatol, 2018,16:1650-1656.e2.
[16] Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. Hepatology, 2019,70:802-811.
[17] Kedarisetty CK, Anand L, Bhardwaj A, et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology, 2015,148:1362-1370.e7.
[18] Fiuza C, Salcedo M, Clemente G, et al. Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol, 2002,9:433-439.
[19] Rolando N, Clapperton M, Wade J, et al. Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol, 2000,12:1135-1140.
[20] Alvarenga DM, Mattos MS, Lopes ME, et al. Paradoxical Role of Matrix Metalloproteinases in Liver Injury and Regeneration after Sterile Acute Hepatic Failure. Cells, 2018,7:247.
[21] Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol, 2014,109:1417-1423.
[22] Anand L, Bihari C, Kedarisetty CK, et al. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis. Liver Int, 2019,39:115-126.
[23] Piscaglia AC, Arena V, Passalacqua S, et al. A case of granulocyte-colony stimulating factor/plasmapheresis-induced activation of granulocyte-colony stimulating factor-positive hepatic progenitors in acute-on-chronic liver failure. Hepatology, 2015,62:649-652.
[24] 康文, 刘正稳, 韩群英, 等. 粒细胞集落刺激因子对大鼠急性肝衰竭肝细胞凋亡的影响. 中华医学杂志, 2008:980-984.
[25] Chen H, Tang S, Liao J, et al. Therapeutic effect of human umbilical cord blood mesenchymal stem cells combined with G-CSF on rats with acute liver failure. Biochem Biophys Res Commun, 2019,517:670-676.
[26] 周培, 于淙, 渠淑云. 集落刺激因子治疗终末期酒精性肝病的临床对照研究. 肝脏, 2020,25:521-524.
[27] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华肝脏病杂志, 2019:18-26.
[28] Saha BK, Mahtab MA, Akbar S, et al. Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage. Hepatol Int, 2017,11:540-546.
[29] Philips CA, Augustine P, Rajesh S, et al. Granulocyte?Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit. J Clin Exp Hepatol, 2020,10:124-134.
[30] De A, Kumari S, Singh A, et al. Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients with Decompensated Cirrhosis in a Randomized Trial. Clin Gastroenterol Hepatol, 2021,19:375-383.e5.
[31] Verma N, Kaur A, Sharma R, et al. Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial. Hepatology, 2018,68:1559-1573.
[32] Newsome PN, Fox R, King AL, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol, 2018,3:25-36.
[33] Becker P, Schwebig A, Brauninger S, et al. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance. Transfusion, 2016,56:3055-3064. |
